These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 25511811)

  • 1. Influence of β-cyclodextrin on the Properties of Norfloxacin Form A.
    Chierentin L; Garnero C; Chattah AK; Delvadia P; Karnes T; Longhi MR; Salgado HR
    AAPS PharmSciTech; 2015 Jun; 16(3):683-91. PubMed ID: 25511811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
    Srivalli KM; Mishra B
    AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfamethoxazole:hydroxypropyl-β-cyclodextrin complex: preparation and characterization.
    Garnero C; Aiassa V; Longhi M
    J Pharm Biomed Anal; 2012 Apr; 63():74-9. PubMed ID: 22361661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of β-cyclodextrin-norfloxacin inclusion complexes. Part 2. Inclusion mode and stability studies.
    Mendes C; Buttchevitz A; Barison A; Ocampos FM; Bernardi LS; Oliveira PR; Silva MA
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):131-40. PubMed ID: 25488143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Preparation Method on the Formation of True Nimodipine SBE-β-CD/HP-β-CD Inclusion Complexes and Their Dissolution Rates Enhancement.
    Semcheddine F; Guissi Nel I; Liu X; Wu Z; Wang B
    AAPS PharmSciTech; 2015 Jun; 16(3):704-15. PubMed ID: 25511809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis.
    Pralhad T; Rajendrakumar K
    J Pharm Biomed Anal; 2004 Feb; 34(2):333-9. PubMed ID: 15013147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of β-cyclodextrin-norfloxacin inclusion complexes. Part 1. Preparation, physicochemical and microbiological characterization.
    Mendes C; Wiemes BP; Buttchevitz A; Christ AP; Ribas KG; Adams AI; Silva MA; Oliveira PR
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):119-29. PubMed ID: 25488142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. insights into novel supramolecular complexes of two solid forms of norfloxacin and β-cyclodextrin.
    Chattah AK; Mroue KH; Pfund LY; Ramamoorthy A; Longhi MR; Garnero C
    J Pharm Sci; 2013 Oct; 102(10):3717-24. PubMed ID: 23904189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of mosapride citrate inclusion complexes with natural and synthetic cyclodextrins.
    Ali AA; Sayed OM
    Pharm Dev Technol; 2013; 18(5):1042-50. PubMed ID: 22206481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving furosemide polymorphs properties through supramolecular complexes of β-cyclodextrin.
    Garnero C; Chattah AK; Longhi M
    J Pharm Biomed Anal; 2014 Jul; 95():139-45. PubMed ID: 24667568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on trimethoprim:hydroxypropyl-β-cyclodextrin: aggregate and complex formation.
    Garnero C; Zoppi A; Genovese D; Longhi M
    Carbohydr Res; 2010 Nov; 345(17):2550-6. PubMed ID: 20933225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
    Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
    Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution enhancement of cefdinir with hydroxypropyl-β-cyclodextrin.
    Guo B; Zhong S; Li N; Li X; Yi J; Jin M
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1638-43. PubMed ID: 24087855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Water-soluble Complex of Curcumin with Cyclodextrins: Enhanced Physical Properties For Ocular Drug Delivery.
    Maria DN; Mishra SR; Wang L; Abd-Elgawad AH; Soliman OA; El-Dahan MS; Jablonski MM
    Curr Drug Deliv; 2017 Sep; 14(6):875-886. PubMed ID: 27501714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
    Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
    Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation & characterization of solid inclusion complex of cefpodoxime proxetil with beta-cyclodextrin.
    Bhargava S; Agrawal GP
    Curr Drug Deliv; 2008 Jan; 5(1):1-6. PubMed ID: 18220545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Stability and the Pharmaceutical Properties of Norfloxacin Form C Through Binary Complexes with β-Cyclodextrin.
    Garnero C; Chattah AK; Aloisio C; Fabietti L; Longhi M
    AAPS PharmSciTech; 2018 Jul; 19(5):2255-2263. PubMed ID: 29748896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preformulative assessment of preformed complexes of gemfibrozil, with cyclodextrins.
    Ain S; Philip B; Pathak K
    PDA J Pharm Sci Technol; 2008; 62(4):300-8. PubMed ID: 19174958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
    Sinha VR; Nanda A; Chadha R; Goel H
    Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.